These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23311989)

  • 21. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
    Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
    Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
    Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT
    Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
    Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
    Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results.
    Van Campenhout H; Marbaix S; Derde MP; Annemans L
    Clin Drug Investig; 2008; 28(8):509-21. PubMed ID: 18598097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
    Steinbach WJ
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.
    Bourke P; Castro P; Rabagliati R; Beltran C; Verdejo H; Winter JL; Bourge RC
    Transpl Infect Dis; 2012 Oct; 14(5):E56-9. PubMed ID: 22852999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
    Pagano L; Valentini CG; Fianchi L; Caira M
    J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
    Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
    Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
    Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C
    BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics of voriconazole.
    Rubio-Terrés C; Grau S
    Expert Opin Pharmacother; 2010 Apr; 11(6):877-87. PubMed ID: 20201729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of current drug therapies for invasive aspergillosis.
    Traunmüller F; Popovic M; Konz KH; Smolle-Jüttner FM; Joukhadar C
    Pharmacology; 2011; 88(3-4):213-24. PubMed ID: 21986253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.
    Liu A; Xiong L; Wang L; Zhuang H; Gan X; Zou M; Wang X
    BMC Infect Dis; 2024 Jun; 24(1):581. PubMed ID: 38867163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in causes of death over time after treatment for invasive aspergillosis.
    Wingard JR; Ribaud P; Schlamm HT; Herbrecht R
    Cancer; 2008 May; 112(10):2309-12. PubMed ID: 18338758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.